Monday, April 15, 2019

Contract drug manufacturer Catalent Inc. agreed to buy closely held Paragon Bioservices Inc. for $1.2 billion, according to people familiar with the matter, the latest deal in the emerging market for gene-therapy drugs.


from MarketWatch.com - Top Stories https://on.mktw.net/2P9SHFf

0 comments:

Post a Comment

Followers

Contact Form

Name

Email *

Message *

Popular Posts

FOLLOW BY EMAIL

Enter your email address:

Delivered by FeedBurner